Technical Analysis for MDCO - The Medicines Company

Grade Last Price % Change Price Change
grade A 83.955 -0.14% -0.12
MDCO closed down 0.04 percent on Wednesday, December 4, 2019, on 1.23 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical MDCO trend table...

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 0.18%
Pocket Pivot Bullish Swing Setup 0.18%
Volume Surge Other 0.18%
Calm After Storm Range Contraction 0.18%
Narrow Range Bar Range Contraction 0.18%
NR7 Range Contraction 0.18%
New 52 Week High Strength 0.18%
Upper Bollinger Band Walk Strength 0.18%
Wide Bands Range Expansion 0.18%
Above Upper BB Strength 0.18%

Older signals for MDCO ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
The Medicines Company provides medical solutions for patients in acute and intensive care hospitals worldwide. The company markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, as well as for use in patients undergoing percutaneous coronary intervention; Recothrom, a human recombinant thrombin used as an aid to hemostasis; Cleviprex, an intravenous small molecule calcium channel blocker for blood pressure reduction; and ready-to-use formulation of Argatroban for the treatment of thrombosis. Its products under development include Cangrelor, an intravenous small molecule antiplatelet agent that is Phase III clinical trial for the prevention of platelet activation and aggregation; Oritavancin, an investigational intravenous antibiotic, which is in Phase III clinical trial for the treatment of acute bacterial skin and skin structure infections; and IONSYS, a pre-registration stage product for the short-term management of acute postoperative pain. The company's products under development also comprise MDCO-157, a pre-registration stage product for platelet inhibition in patients suffering from acute coronary syndrome (ACS); MDCO-216, a novel biologic product that is in Phase I trial to reverse atherosclerotic plaque development and reduce the risk of coronary events in patients with ACS; and ALN-PCS, a development program, which is in Phase I trial for the treatment of hypercholesterolemia. In addition, it offers acute care generic products for use in the cardiovascular, neurocritical care, and serious infection therapeutic areas; and promotes BRILINTA, an oral tablet antiplatelet medicine. The company has collaboration agreements with Alnylam Pharmaceuticals, Inc. and AstraZeneca LP. The Medicines Company was founded in 1996 and is based in Parsippany, New Jersey.
Pain Chemical Compounds Organic Compounds Infection Skin And Skin Structure Infections Thrombosis Hypercholesterolemia Medical Emergencies Acute Coronary Syndrome Direct Thrombin Inhibitors Organochlorides Percutaneous Transluminal Coronary Angioplasty Thioethers

Is MDCO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Indicators
Indicator Value
52 Week High 84.3
52 Week Low 16.69
Average Volume 3,893,729
200-Day Moving Average 40.3054
50-Day Moving Average 58.9314
20-Day Moving Average 67.6575
10-Day Moving Average 79.691
Average True Range 2.8782
ADX 42.66
+DI 53.7087
-DI 12.2178
Chandelier Exit (Long, 3 ATRs ) 75.6654
Chandelier Exit (Short, 3 ATRs ) 57.7946
Upper Bollinger Band 94.5225
Lower Bollinger Band 40.7925
Percent B (%b) 0.81
BandWidth 79.414699
MACD Line 8.3333
MACD Signal Line 6.5703
MACD Histogram 1.763
Fundamentals Value
Market Cap 6.06 Billion
Num Shares 72.1 Million
EPS -10.00
Price-to-Earnings (P/E) Ratio -8.41
Price-to-Sales 20.03
Price-to-Book 14.81
PEG Ratio -0.04
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 84.33
Resistance 3 (R3) 84.33 84.26 84.28
Resistance 2 (R2) 84.26 84.19 84.25 84.27
Resistance 1 (R1) 84.16 84.15 84.13 84.16 84.25
Pivot Point 84.09 84.09 84.07 84.08 84.09
Support 1 (S1) 83.99 84.02 83.96 83.99 83.89
Support 2 (S2) 83.92 83.98 83.91 83.87
Support 3 (S3) 83.82 83.92 83.86
Support 4 (S4) 83.82